Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

CVR Medical Corp V.CVM.H

Alternate Symbol(s):  CRRVF

CVR Medical Corp. is a medical technology organization. The Company is focused on the development and advancement of technology at work within the healthcare sector. The Company’s Carotid Stenotic Scan (CSS) is a diagnostic tool designed to detect and determine a level of carotid narrowing for the purpose of identifying patients at risk for Ischemic Stroke. The CSS provides a synergistic tool which complements other stroke screening technology, such as Duplex Doppler ultrasound (DUS), magnetic resonance angiography (MRA), and computed tomography angiography (CTA). The CSS is 100% non-invasive and does not require the use of harmful dyes. It offers its product to patients, payers, and healthcare providers. The CVR device uses only sound wave analysis to detect the presence of arterial stenosis.


TSXV:CVM.H - Post by User

Bullboard Posts
Comment by Nastroon Jan 15, 2019 3:25am
81 Views
Post# 29231715

RE:RE:RE:RE:RE:RE:RE:RE:RE:Insider Trading

RE:RE:RE:RE:RE:RE:RE:RE:RE:Insider TradingThe deal was actually with a Chinese company.  It was released on 18 Jan last year.  It involves an upfront payment of $ 20m and a 35% of a JV.  There has not been any other reports on it since so I guess it’s still on going.  There was also a press release with some fairly sketchy details of a Korean deal as well.  They were made to restate the Chinese deal by the exchange with more information following the initial release.

Also if you look in the presentation there are quite a few countries highlighted in colour where deals or at least initial discussions are going.  Could be that many are waiting to see if they get FDA approval first before signing on the dotted line as this is widely seen as the gold standard?
Bullboard Posts